Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.

Journal of hematology & oncology·2026

Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026

Same author

Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.

Microbiology spectrum·2026

Same author

Fucosylation in cancer and its role in anti-tumor immunity.

European journal of cell biology·2026

Same author

Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer.

Nature communications·2026

Same author

Cytotoxic CD39<sup>+</sup> tumor-associated NK cells respond to NKG2A blockade in lung cancer.

Science immunology·2026

Search research articles

Related Experiment Video

Updated: May 27, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Basic Concepts and Indications of CAR T Cells.

Jana van den Berg^1,2, Heinz Läubli^2,3,4, Nina Khanna^2,3,5

¹Division of Hematology, University Hospital Basel, Basel, Switzerland.

Hamostaseologie

|February 19, 2025

Summary

Chimeric antigen receptor (CAR) T cell therapy offers a revolutionary approach to treating blood cancers. This review covers CAR T cell therapy

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: May 27, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunology
Oncology
Biotechnology

Background:

Chimeric antigen receptor (CAR) T cell therapy has transformed cancer immunotherapy, especially for hematological malignancies.
This personalized treatment involves genetically modifying a patient's T cells to target cancer antigens, offering hope against refractory diseases.

Purpose of the Study:

To provide a comprehensive overview of CAR T cell therapy.
To discuss its fundamental concepts, clinical applications, and challenges in hematological malignancies.

Main Methods:

Review of existing literature on CAR T cell therapy.
Analysis of clinical applications and outcomes in hematological malignancies.

Main Results:

CAR T cell therapy has shown high efficacy in previously untreatable hematological cancers.
Significant challenges remain, including manufacturing complexity, toxicity management, resistance, and cost.

Conclusions:

CAR T cell therapy is a powerful tool in cancer immunotherapy with a rapidly expanding clinical role.
Ongoing research focuses on overcoming current challenges to improve long-term efficacy and accessibility.